143 related articles for article (PubMed ID: 6293630)
1. A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.
Allegra JC; Woodcock TM; Richman SP; Bland KI; Wittliff JL
Breast Cancer Res Treat; 1982; 2(1):93-9. PubMed ID: 6293630
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Allegra JC
Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
[TBL] [Abstract][Full Text] [Related]
3. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Lippman ME; Cassidy J; Wesley M; Young RC
J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
[TBL] [Abstract][Full Text] [Related]
4. Cytoxan, epirubicin, methotrexate and 5-fluorouracil with hormonal synchronization (tamoxifen/premarin) in advanced breast cancer. Preliminary results.
Zaniboni A; Simoncini E; Marpicati P; Gorni F; Cervi GC; Marini G
Chemioterapia; 1986 Oct; 5(5):341-6. PubMed ID: 3024851
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.
Eisenhauer EA; Bowman DM; Pritchard KI; Paterson AH; Ragaz J; Plenderleith I; Geggie PH; Maxwell I
Cancer Treat Rep; 1984 Nov; 68(11):1421-2. PubMed ID: 6094005
[No Abstract] [Full Text] [Related]
6. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
Lippman ME; Cassidy J; Wesley M; Young RC
J Clin Oncol; 1984 Jan; 2(1):28-36. PubMed ID: 6321686
[TBL] [Abstract][Full Text] [Related]
7. Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy.
Bitran JD; Desser RK; Shapiro CM; Michel A; Kozloff MF; Billings AA; Recent W
Cancer; 1983 Feb; 51(3):381-4. PubMed ID: 6821824
[TBL] [Abstract][Full Text] [Related]
8. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
Cancer; 1980 Feb; 45(4):735-41. PubMed ID: 6986969
[TBL] [Abstract][Full Text] [Related]
10. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Mouridsen HT; Andersson M; Pedersen L
Semin Oncol; 1986 Mar; 13(1 Suppl 1):39-41. PubMed ID: 3952520
[TBL] [Abstract][Full Text] [Related]
11. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
12. Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
Andersson M; Mouridsen HT
Acta Oncol; 1988; 27(3):235-9. PubMed ID: 3415852
[TBL] [Abstract][Full Text] [Related]
13. Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.
Chang JC; Wergowske G
Cancer; 1981 Dec; 48(11):2503-6. PubMed ID: 7296498
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
[TBL] [Abstract][Full Text] [Related]
15. Principles and indications of endocrine treatment of advanced breast cancer.
Mouridsen HT; Palshof T
Recent Results Cancer Res; 1980; 71():112-7. PubMed ID: 7367722
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J
Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067
[TBL] [Abstract][Full Text] [Related]
19. The use of mammography in breast preservation in locally advanced breast cancer.
Pierce L; Adler D; Helvie M; Lichter A; Merajver S
Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):571-7. PubMed ID: 8621280
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
Creech RH; Catalano RB; Dierks KM; Shah MK
Cancer Treat Rep; 1984 Dec; 68(12):1499-501. PubMed ID: 6548936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
